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Abstract Characteristic cardiac valve abnormalities and left
ventricular hypertrophy are present in untreated patients with
mucopolysaccharidosis type VI (MPSVI). Cardiac ultrasound
was performed to investigate these findings in subjects during
long-term enzyme replacement therapy (ERT) with recombi-
nant human arylsulfatase B (rhASB, rhN-acetylgalactosamine
4-sulfatase, galsulfase, Naglazyme®). Studies were conducted
in 54 subjects before ERTwas begun and at specific intervals
for up to 96 weeks of weekly infusions of rhASB at 1 mg/kg
during phase 1/2, phase 2, and phase 3 trials of rhASB. At
baseline, mitral and aortic valve obstruction was present and
was significantly greater in those ≥12 years of age.Mild mitral
and trace aortic regurgitation were present, the former being
significantly greater in those <12 years. Left ventricular hy-
pertrophy, with averaged z-scores ranging from 1.6–1.9 SD
greater than normal, was present for ages both <12 and
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≥12 years. After 96 weeks of ERT, ventricular septal hyper-
trophy regressed in those <12 years. For those ≥12 years,
septal hypertrophy was unchanged, and aortic regurgitation
increased statistically but not physiologically. Obstructive
gradients across mitral and aortic valves remained unchanged.
The results suggest that long-term ERT is effective in reducing
intraventricular septal hypertrophy and preventing progres-
sion of cardiac valve abnormalities when administered to
those <12 years of age.
Introduction
Mucopolysaccharidosis type VI (MPS VI, Maroteaux-Lamy
syndrome) is a lysosomal storage disease caused by functional
absence of the enzyme N-acetylgalactosamine 4-sulfatase
(arylsulfatase B or ASB; E.C. 3.1.6.12). Absence of this en-
zyme results in the accumulation of dermatan-sulfated glyco-
saminoglycans (GAGs) within lysosomes of various tissues
including bones, cartilage, lungs, airways, and the cardiovas-
cular system (Neufeld and Muenzer 2001). The progressive
accumulation of these substances results in multi-organ system
dysfunction such as joint contractures, short stature, dysostosis
multiplex, decreased pulmonary function, cardiac abnormali-
ties and, ultimately, shortened life span (Neufeld and Muenzer
2001). The severity of the clinical findings is variable but, in a
recent survey of 121 MPS VI subjects, an accelerated clinical
course was associated with urinary excretion of GAGs in
excess of 200 μg/mg creatinine (Swiedler et al. 2005).
Evaluation of the heart in individuals with untreated MPS
VI by cardiac ultrasound has been reported by several inves-
tigators (Lael et al. 2010; Dangel 1998; Wippermann et al.
1995; Azevedo et al. 2004; Scarpa et al. 2009; Fesslova et
al. 2009). The characteristic cardiac abnormalities of MPS
VI include ventricular hypertrophy and a progressive thick-
ening of mitral and aortic valves resulting in valvular regur-
gitation, stenosis, or both. Until now the effects of enzyme
replacement therapy (ERT) upon the heart in MPS VI have
not been reported.
Previous phase 1, 2, and 3 studies have shown that
treatment of individuals with MPS VI by ERT with recom-
binant human N-acetylgalactosamine 4-sulfatase (rhASB;
galsulfase; Naglazyme®) is safe, rapidly reduces urinary
GAG levels, and improves endurance as measured by 6-
or 12-min walk and pulmonary function testing (Harmatz et
al. 2004, 2005, 2006). Further analysis of pooled data from
the clinical ERT trials and the survey study has demonstrat-
ed safety and significant long-term increases in endurance,
pulmonary function, and growth when galsulfase is admin-
istered for 96 weeks or more (Harmatz et al. 2008, 2010;
Decker et al. 2010). The purpose of this report is to analyze
cardiac ultrasound data obtained during phase 1, 2, and 3
clinical ERT trials to determine the effects of 96 weeks of
ERT upon the characteristic cardiac findings in individuals
with MPS VI.
Methods
Previous reports have detailed the study design and out-
comes of the phase I/2, 2, and 3 galsulfase trials in subjects
with MPS VI (Harmatz et al. 2004, 2005, 2006, 2008,
2010); details of the clinical trials are outlined in Table 1.
Cardiac ultrasound was performed as part of the clinical
evaluation of subjects in the phase 1/2, 2, and 3 clinical
trials at baseline, before ERT was begun, and at intervals of
24–48 weeks and 72–96 weeks after initiation of ERT
(Table 2). An Institutional Review Board (IRB) or Ethics
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Committee (EC) at each participating clinical site approved
each study. All adult patients and parent/guardians gave
written consent; patients younger than 18 years old gave
written assent according to local IRB regulations.
Archived ultrasound data, collected from subjects who
had participated in phase 1/2, 2, or 3 clinical trials, were
reviewed and tabulated for this study. The original echoes
were obtained and analyzed at the individual sites; original
echo tapes were unavailable for further review. Each ar-
chived measurement was reviewed for reliability by a single
person (E.B.). Discrepancies were resolved by discussion
with individual sites. The entire data set was then subjected
to statistical evaluation. Height, weight, and urinary GAG
content at study entry were analyzed for the 54 subjects who
participated in phase 1/2, 2, or 3 galsulfase trials.
Cardiac ultrasound investigations were performed and
interpreted by study protocol at the participating sites during
each study point as indicated in Table 2. Measurements in-
cluded M-mode determination of left ventricular chamber
dimension in diastole (LVED) and systole (LVES), as well
as diastolic left ventricular posterior wall (LVPWd) and intra-
ventricular septal (IVSd) thicknesses. Body surface areas were
calculated by the method of duBois for each subject, and z-
scores were determined from the measured value for each
chamber dimension and wall thickness at each evaluation
(Dyar 2012). The individual z-scores from each subject for
each parameter at each time point were summed and averaged
to obtain the mean z-score displayed in the tables. By use of
the z-score, chamber dimensions and wall thicknesses from
subjects of differing body surface areas can be compared, and
the changes within a particular subject tracked over time
(Kampmann et al. 2000). With this system, a z-score of 0
represents the expected normal value for a given body surface
area, a positive z-score is a standard deviation value greater
than expected normal, and a negative z-score is a value less
than expected normal. Left ventricular shortening fraction
(SF) was calculated by standard methods (Lopez et al. 2010).
Doppler interrogation of flow acceleration across, and
regurgitation from, all cardiac valves was measured by
pulsed, continuous, and color flow Doppler methods. Peak
systolic gradient was recorded across aortic valves; mean
diastolic gradient was measured across mitral valves; and
both were compared to normal values (Lopez et al. 2010;
Hatle and Angelsen 1985; Baumgartner et al. 2009; Sohn
and Kim 2001). Valvular regurgitation was assigned the
following scores: 0 (none), 1 (trace), 2 (mild), 3 (moderate),
and 4 (severe). Mitral and aortic valve gradients and regur-
gitation scores for the cohort were recorded at baseline, 48
and 96 weeks. Three subjects had undergone mitral valve
repair or replacement (two before and one during the trials)
or aortic valvuloplasty (one before the trials). For purposes
of this review, peak systolic aortic gradient was the only
variable analyzed after mitral valve replacement in these
three subjects. Additional cardiac anomalies were noted
when found.
Ultrasound reports were obtained and reviewed retro-
spectively. Data from the phase I/2 study and phase 3 study
were analyzed for differences between combined reduced
dose (0.2 mg/kg, phase 1/2 low-dose group) or delayed
dose (phase 3, placebo group) and standard dose (1 mg/kg)
treatment. Data were pooled from all three treatment trials
(phase 1/2, phase 2, and phase 3) and then analyzed for
baseline values and for differences between baseline and
24–48 and 72–96 weeks of treatment with galsulfase.
Data were analyzed using all available data and then re-
analyzed using only those subjects for whom data were
available at all three study points (baseline, weeks 48 and
96) of galsulfase treatment.
Table 1 Summary of study populations
Study Study
design
Study
dates
Study duration
(weeks)
Patients enrolled/
completed
Dose of
rhASB (mg/kg)
Age (years),
mean ± SD (range)
Sex (M/F)
Phase 1/2 Double-blinded, randomized,
dose comparison/open-label
extension
Jan 2001–Dec 2005 240 7/5 0.2 12.0±3.8 (7–16) 4/3
Phase 2 Open-label, nonrandomized 2002–2006 144 10/10 1.0 12.1±5.3 (6–21) 7/3
Phase 3 Double-blinded,
placebo-controlled,
randomized/open-label
extension
2003–2006 96 39/38 1.0 13.7±6.5 (rhASB);
10.7±4.4 (placebo);
(6–29)
13/26
rhASB Recombinant human arylsulfatase B
Table 2 Schedule of cardiac ultrasound evaluations
Study Treatment week
0 24 48 72 96
Phase 1/2 X X X X X
Phase 2 X X X
Phase 3 rhASB/rhASB X X X
Phase 3 placebo/rhASB X X X
rhASB Recombinant human arylsulfatase B
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Statistical analysis
Initial analyses were based on analysis of variance models
or Student’s t-test to assess differences in demographic
variables at baseline between the various subgroups com-
pared. Analysis of differences by gender and by age
(<12 years versus ≥12 years) were made both at baseline
and between weeks 24–48 and 72–96. Finally, the major
hypotheses were evaluated using general linear models and
performed for all subjects for whom data were available and
again for subjects for whom data were available at all three
study points of galsulfase treatment (Pettersen et al. 2008;
Diggle et al. 2012). The models investigated differences
over the three time points between and within each of the
two treatment groups (reduced or delayed vs. standard
dose). To estimate more efficient and unbiased regression
parameters of data collected as repeated measures over time,
the generalized estimating equation approach of Zeger and
Liang was used (Diggle et al. 2012). This allowed specifi-
cation of a working correlation matrix that accounts for the
within-subject correlations. A significance level of 0.05 was
used for all statistical tests. Data were analyzed using SAS
version 9.2.
Results
Baseline studies
The mean age for the entire group was 11.8±5.4 (range 6–
29) years; 37 (68 %) were females and 17 (32 %) males. The
mean urinary GAG of 341.4±120.5 μg GAG/mg creatinine
was elevated and concomitant mean age-adjusted stature
(102.5±13 cm) reduced (Table 3), suggesting more severe
MPS VI disease in this group of individuals as has been
previously reported by others (Swiedler et al. 2005). Height,
weight, and body surface area differed by age (p00.008,
0.0008, and 0.001, respectively, data not shown); however,
there was no difference in height, weight, or urinary GAG
either by gender (p00.373, 0.373, and 0.235, respectively)
or in GAG by age (p00.224).
Cardiac dimensions and function
Cardiac findings for the 54 subjects before the initiation of
ERT are listed in Table 4. Males and females did not signif-
icantly differ in age (12.2±6 vs. 11.7±5.2 years, p00.742)
or in any measured cardiac parameter (data not shown), thus
both genders were grouped together for all subsequent anal-
yses. The mean z-score of left ventricular end-diastolic
dimension (LVED) was within 1 SD of normal at baseline
for all participants, regardless of age. By contrast, the mean
z-score of LVES was 1.2 SD smaller than normal in those
≥12 years of age, a finding that just reached statistical
significance (p00.039) when compared to those <12 years.
Despite this finding, SF was within normal limits for all
participants, regardless of age. The mean z-scores for left
ventricular wall thicknesses (LVPWd, IVSd) were increased
to 1.4 –1.9 SD greater than normal at baseline for all partic-
ipants regardless of age (p00.858 and 0.229, respectively) in
keeping with the infiltrative nature of the lysosomal storage
diseases.
Cardiac valves
Before ERT, the mean mitral valve gradient of 7.28±
5.68 mmHg was higher than normal (<5 mmHg) (Lopez et
al. 2010; Hatle and Angelsen 1985; Baumgartner et al.
2009; Sohn and Kim 2001), indicating obstruction to flow
(mitral stenosis) prior to institution of galsulfase therapy.
The mitral gradient was significantly greater for subjects
≥12 vs. <12 years (9.69±6.46 vs. 5.15±3.98 mmHg, re-
spectively, p00.022) (Table 4). Two of the three mitral valve
replacements were performed in those >12 years of age. For
the entire cohort, the mitral valve was mildly regurgitant at
baseline (score 1.35±1.05). In contrast to mitral stenosis,
mitral regurgitation was significantly less in older subjects
(mitral regurgitation score 1.00±0.93 vs. 1.58±1.01 for
subjects ≥12 vs. <12 years, p00.044).
The aortic valve was less affected than the mitral before
ERT. The peak systolic gradient across the aortic valve for
the entire group of 13.72±10.78 mmHg was at the upper
limit of childhood normal values (11–13 mmHg) (Lopez et
al. 2010; Hatle and Angelsen 1985; Baumgartner et al.
Table 3 Demographics
**p00.008 for height by age
groups
Subjects Baseline height (cm) Baseline GAG (μg glycosaminoglycan/mg creatinine)
Mean ± SD Mean ± SD
All (n054) 102.54±12.99 341.43±120.53
<12 years (n033) 98.9±11.0** 357.5±119.5
≥12 years (n021) 108.3±13.98** 316.23±120.65
Male (n017) 104.9±13.4 312.5±101.4
Female (n037) 101.5±12.8 354.72±127.44
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2009; Sohn and Kim 2001). As with the mitral valve, the
aortic gradient was significantly greater in older participants
(18.77±13.68 vs. 9.24±3.90 mmHg, p00.015). Aortic val-
vuloplasty was performed in one subject >12 years of age
before the initiation of therapy. Aortic regurgitation was
barely perceptible at baseline (aortic regurgitation score of
0.53±0.87 equivalent to trace regurgitation) and did not
differ between older and younger subjects (p00.104 for
age ≥12 vs. <12 years).
Other cardiac anomalies
Other cardiac anomalies were rare in this group of subjects,
but included one subject with partial anomalous pulmonary
venous return, sinus venosus atrial septal defect, and pul-
monary stenosis, who had undergone pulmonary valvotomy.
Studies after galsulfase treatment
Cardiac dimensions and function
Data from the entire cohort are presented in Table 5, while
data from subjects in whom all three time points were avail-
able (before ERT, weeks 24–48, and weeks 72–96) are pre-
sented in Table 6. After 96 weeks of enzyme, the mean z-score
for LVED remained unchanged (p00.150, p00.146, respec-
tively) and normal (Table 5, Table 6) for both groups. The
mean z-score for left ventricular systolic dimension (LVES)
increased significantly (p00.034) during therapy for the entire
cohort but not for those in whom all three time points were
available (p00.053), but this change did not adversely affect
cardiac function since the SF remained normal for both groups
throughout the study (p00.208, p00.135, respectively). For
both the entire cohort and for those in whom all three time
points were available, the mean z-score for left ventricular
posterior wall thickness (LVPWd) remained increased and did
not change (p00.551, p00.510, respectively) after 96 weeks
of enzyme, but the mean z-score for IVSd decreased signifi-
cantly (p<0.0001and p<0.0001, respectively) during this pe-
riod. One subject was lost to follow-up after baseline studies.
Analysis of data with and without his inclusion did not alter
results. Prior to combining data from the two groups, we had
examined all data as a function of time, comparing standard
vs. reduced or delayed enzyme. We observed a significant
time versus group interaction (p00.0396) for IVSd (Table 5,
footnote 1, Figure A).
Because there was no statistical difference in wall thick-
ness between the entire cohort and those in whom all three
measurement points were available, we analyzed the data
for those <12 years of age vs. those ≥12 years of age from
the entire cohort. Treatment with galsulfase appeared to
have more effect when administered to those <12 years of
age (Table 7). For those subjects <12 years of age, the
mean z-score for IVSd reflected significantly less hyper-
trophy (p<0.0001) while for those ≥12 years it did not
change (p00.318).
Cardiac valves
After 96 weeks of enzyme, neither mitral valve obstruction
(MMV) nor mitral valve regurgitation (MRS) changed in
either the entire cohort or in those in whom all three mea-
surement points were available (MMV: p00.552, p00.971,
respectively, and MRS: p00.459, p00.402, respectively,
Tables 5 and 6). Aortic valve obstruction remained un-
changed for both the entire cohort and for those in whom
all three time points were available (p00.150, p00.516,
respectively) during the studies, but aortic regurgitation
Table 4 Baseline data from 54 MPS VI subjects enrolled in galsulfase trials
Measurement Normal value Total <12 years ≥12 years p value
n054 n033 n021
Age - 11.8±5.4 (n054) 8.3±1.6 (n033) 17.3±4.6 (n021)
LVED mean z-score 0 −0.16±1.25 (n054) 0.08±1.33 (n033) −0.54±1.02 (n021) 0.076
LVES mean z-score 0 −0.74±1.40 (n054) −0.43±1.31 (n033) −1.23±1.43 (n021) 0.039*
SF (%) ≥28 42.20±6.63 (n054) 41.49±6.28 (n033) 43.31±7.15 (n021) 0.331
LVPWd mean z-score 0 1.86±0.99 (n053) 1.88±1.08 (n033) 1.83±0.85 (n020) 0.858
IVSd mean z-score 0 1.57±0.95 (n054) 1.69±0.99 (n033) 1.37±0.88 (n021) 0.229
AoPSG (mmHg) <10 13.72±10.78 (n034) 9.24±3.90 (n018) 18.77±13.68 (n016) 0.015*
MMV (mmHg) <5 7.28±5.68 (n032) 5.15±3.98 (n017) 9.69±6.46 (n015) 0.022*
Aortic regurgitation 0 0.53±0.87 (n054) 0.68±0.97 (n033) 0.29±0.64 (n021) 0.104
Mitral regurgitation 0 1.35±1.01 (n051) 1.58±1.01 (n031) 1.00±0.93 (n020) 0.044*
LVED Left ventricular chamber dimension in diastole, LVES left ventricular chamber dimension in systole, SF shortening fraction, LVPWd diastolic left
ventricular posterior wall thickness, IVSd diastolic intraventricular septal thickness, AoPSG aortic peak systolic gradient,MMV mean mitral valve gradient
*p-value comparing age <12 years to ≥12 years
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increased significantly (p00.004, p0−0.008, respectively)
while still remaining within the “trace to mild” category. As
discussed above, prior to combining data from the two
groups, we examined the pattern over time for each group
(standard vs. reduced or delayed) to learn if it was similar
for the two groups. We observed a significant time versus
group interaction (p00.019) for aortic regurgitation (Table 5,
footnote 2, Figure B) although again we could not identify
any reasonable explanation as to why this would be the case.
When the entire cohort was analyzed by age <12 vs.
≥12 years, neither mitral nor aortic valve stenosis changed
after 96 weeks of therapy. Mitral regurgitation did not in-
crease in either age group (Table 7) after 96 weeks of
treatment, but aortic valve regurgitation score increased in
those ≥12 years of age (p00.015).
Discussion
The cardiovascular system is progressively and unambigu-
ously affected in individuals with MPS VI. Left ventricular
hypertrophy, as well as anatomic and functional abnormal-
ities of the mitral and aortic valves, have previously been
well described by others (Lael et al. 2010; Dangel 1998;
Wippermann et al. 1995; Azevedo et al. 2004; Scarpa et al.
2009; Fesslova et al. 2009). Our data obtained prior to the
initiation of ERT from a large number of severely affected
subjects with MPS VI support these observations but, more
importantly, describe the cardiac effects of long-term treatment
with galsulfase ERT.
Prior to ERT, left ventricular hypertrophy and mitral
valve stenosis were the most prominent cardiac features
Table 5 ECHO data from MPS VI subjects during galsulfase trials
Echo parameter Baseline (n054) 24–48 weeks (n053) 72–96 weeks (n052) p-value (based on repeated measures
model comparing all three time points)
LVED mean z-score −0.16±1.25 (n054) 0.11±1.17 (n053) −0.10±1.15 (n051) 0.150
LVES mean z-score −0.74±1.40 (n054) −0.28±1.37* (n052) −0.53±1.30 (n051) 0.034
SF (%) 42.20±6.63 (n054) 40.35±6.65 (n053) 40.40±8.11 (n051) 0.208
LVPWd mean z-score 1.86±0.99 (n053) 1.62±1.94 (n053) 1.64±0.97 (n051) 0.551
IVSd mean z-score 1.57±0.95 (n054) 1.14±0.86* (n053) 0.97±0.89* (n051) <0.0001a
AoPSG (mmHg) 13.72±10.78 (n034) 11.78±6.89 (n037) 12.99±9.00 (n034) 0.150
MMV (mmHg) 7.28±5.68 (n032) 7.75±6.63 (n034) 7.13±5.64 (n030) 0.552
Aortic regurgitation 0.53±0.87 (n054) 0.73±0.97* (n053) 0.88±0.99* (n050) 0.004b
Mitral regurgitation 1.35±1.01 (n051) 1.42±0.89 (n051) 1.51±0.73 (n047) 0.459
LVED Left ventricular chamber dimension in diastole, LVES left ventricular chamber dimension in systole, SF shortening fraction, LVPWd diastolic left
ventricular posterior wall thickness, IVSd diastolic intraventricular septal thickness, AoPSG aortic peak systolic gradient,MMVmean mitral valve gradient
*p<0.05 compared to baseline
aWe observed a significant time versus group interaction (p00.0396) for IVSd. Data shown in Figure A as mean ± SD
Figure A: IVSd z-score
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We observed a significant time versus group interaction (p00.019) for aortic regurgitation. Data shown in Figure B as mean ± SD
Figure B: Aortic Regurgitation Score
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found by this study. Left ventricular hypertrophy was se-
vere, with mean z-scores approaching 2 SD greater than
normal, and was found in subjects of all ages. The mean
gradient across the mitral valve was elevated at baseline and
increased significantly when those <12 years of age were
compared to those ≥12. Mitral valve replacement, per-
formed in three subjects before, or during, these studies
confirmed the severity of this finding. By contrast, mitral
valve regurgitation, usually a more common finding in most
MPS VI pediatric reports (Lael et al. 2010; Dangel 1998;
Wippermann et al. 1995; Azevedo et al. 2004; Scarpa et al.
2009; Fesslova et al. 2009) was only mild in our subjects.
The presence of mitral stenosis, rather than regurgitation,
has been found in older individuals with MPS VI (Diggle et
al. 2012; Marwick et al. 1992; Tan et al. 1992) and is
consistent with the older age of the subjects in this study.
Aortic valve obstruction at baseline was significantly
greater in those 12 years of age or older but, when compared
to mitral obstruction, was milder. Only one subject under-
went aortic valvuloplasty prior to initiation of enzyme treat-
ment. Only trace aortic regurgitation was present at baseline,
a finding considered not physiologically significant.
Long-term enzyme replacement therapy with galsulfase
was associated with maintenance of normal left ventricular
function in all subjects in this study and regression of left
ventricular septal hypertrophy in those who initiated treat-
ment before 12 years of age. This remained true when we
evaluated the entire cohort as well as when we analyzed
only those in whom all three measurement points were
available. During the course of this study, cardiac valve
stenosis neither worsened nor improved, regardless of age.
Aortic valve regurgitation increased significantly—but not
physiologically—after 96 weeks of enzyme replacement in
subjects ≥12 years of age. Although this finding had little
physiologic consequence to these individuals, it may imply
that cardiac valve pathology, once begun, may not be
Table 7 ECHO data from MPS VI subjects by age during galsulfase trials
Echo parameter Age <12 years p-value Age ≥12 years p-value
Baseline 96 weeks Baseline 96 weeks
LVED mean z-score 0.08±1.33 (n033) −0.30±1.15 (n025) 0.219 −0.54±1.02 (n021) −0.09±1.14 (n026) 0.584
LVES mean z-score −0.43±1.31 (n033) −0.59±1.19 0.830 1.37±0.88 (n021) 1.04±0.91 (n026) 0.265
SF (%) 41.49±6.28 (n033) 38.74±9.80 0.247 43.31±7.15 (n021) 42.00±5.83 (n026) 0.747
LVPWd mean z-score 1.88±1.08 (n033) 1.56±1.03 (n025) 0.368 1.83±0.85 (n020) 1.72±0.93 (n026) 0.980
IVSd mean z-score 1.69±0.99 (n033) 0.89±0.87 (n025) <0.0001 1.37±0.88 (n021) 1.04±0.91 (n026) 0.318
AoPSG (mmHg) 9.24±3.90 (n018) 10.06±4.48 (n018) 0.993 18.77±13.68 (n016) 16.29±12.33 (n016) 0.790
MMV (mmHg) 5.15 ±3.98 (n017) 6.57±6.80 (n014) 0.3745 9.69±6.46 (n015) 7.62±4.58 (n016) 0.999
Aortic regurgitation 0.68±0.97 (n033) 0.81±0.83 0.080 0.29±0.64 (n021) 0.94±1.13 (n026) 0.015
Mitral regurgitation 1.58±1.01 (n031) 1.56±0.68 (n024) 0.983 1.00±0.93 (n020) 1.46±0.78 (n023) 0.218
LVED Left ventricular chamber dimension in diastole, LVES left ventricular chamber dimension in systole, SF shortening fraction, LVPWd diastolic left
ventricular posterior wall thickness, IVSd diastolic intraventricular septal thickness, AoPSG aortic peak systolic gradient,MMV mean mitral valve gradient
Table 6 ECHO data from MPS VI subjects during galsulfase trials in which subjects had data on all three time points for each particular variable
ECHO Baseline
(mean ± SD)
48 weeks
(mean ± SD)
96 weeks
(mean ± SD)
ANOVA p-value comparing
weeks 0, 48, 96
LVED mean z-score (n050) −0.13±1.20 0.14±1.10 −0.11±1.16 0.146
LVES mean z-score (n049) −0.76±1.39 −0.31±1.37 −0.55±1.31 0.053
SF % (n050) 42.58±6.71 50.73±6.54 39.72±9.95 0.135
LVPWd mean z-score (n049) 1.91±1.00 1.63±2.00 1.68±0.96 0.510
IVSd mean z-score (n050) 1.61±0.97 1.13±0.86 0.99±0.88 <0.0001
AoPSG (mmHg) (n027) 13.28±11.92 11.81±7.48 12.49±10.20 0.516
MMV (mmHg) (n028) 7.19±4.61 7.14±5.31 7.26±5.77 0.971
Aortic regurgitation (n048) 0.53+ 0.83 0.70±0.93 0.88±0.99 0.008
Mitral regurgitation (n043) 1.33±0.96 1.34±0.85 1.48±0.75 0.402
LVED Left ventricular chamber dimension in diastole, LVES left ventricular chamber dimension in systole, SF shortening fraction, LVPWd diastolic left
ventricular posterior wall thickness, IVSd diastolic intraventricular septal thickness, AoPSG aortic peak systolic gradient,MMV mean mitral valve gradient
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reversible. This progression of aortic regurgitation in the
≥12 years of age group is most likely due to underlying
disease. It is difficult to assess causal relationship with ERT
treatment given that the treatment group was followed for
96 weeks, placebo for 24 weeks, and echocardiography was
not assessed after 24 weeks of treatment or placebo.
Valve obstruction is identified by the measurement of in-
creased Doppler flow velocities across cardiac valves. With a
normal cardiac output, the maximum normal Doppler velocity
across the mitral valve is 1.3 m/s or 6.7 mmHg in children
(Hatle and Angelsen 1985). The mean mitral gradient, a more
accurate measure of obstruction, is obtained by averaging the
instantaneous mitral flow velocities throughout diastole, result-
ing in a lower value. Meanmitral valve gradients <5 mmHg are
consistent withmildmitral obstruction in adults; no values have
been established for children (Baumgartner et al. 2009). The
maximum normal Doppler velocities across the aortic valve in
adults and children are 1.7–1.8m/s, respectively, corresponding
to peak aortic gradients of 11–13 mmHg (Hatle and Angelsen
1985). At baseline the mean mitral and aortic valve gradients in
our subjects exceeded normal values and were greater in older
subjects, consistent with the progressive nature of MPS VI.
The lack of response of the cardiac valves to ERT is
similar to that reported in a small series of MPS VI patients
who underwent hematopoietic stem cell transplantation
(HSCT) and were studied an average of 5 (range 1.8–9)
years after the procedure (Herskhovitz et al. 1999). The
relatively avascular nature of cardiac valve tissue (Dow
and Harper 1932) may, in part, explain the lack of improve-
ment in valve morphology and function with either HSCTor
ERT. Irreversible valve damage accruing over years may
also explain the lack of response in older children and young
adults (such as the subjects of this study) to any type of
intervention. In support of early intervention, galsulfase,
given from 8 weeks of life, has been shown to prevent
cardiac abnormalities altogether (McGill et al. 2010).
Although this study had a large number of subjects with
MPS VI who were studied over a lengthy time period, there
are limitations to the study. The placebo group was followed
for only the first 24 weeks of the phase 3 study. If follow-up
had been extended for a longer time period, other differences
between the placebo and treated groups may have been iden-
tified. The second limitation of this study is that ultrasounds
were performed and analyzed at local sites. The concept of a
central echocardiographic facility to provide reliable and re-
producible data for multicenter pediatric cardiac studies
emerged during the course of these trials (Lipschultz et al.
2001). Cardiac ultrasound in subjects with MPS can be diffi-
cult due to abnormalities of the thorax, poor lung expansion
from hepatomegaly and restrictive lung disease, and inability
to extend the neck. Comparison of M-mode measurements
made in the field versus the central location in two different
pediatric studies (Lipschultz et al. 2001; Dai et al. 1999)
suggests that repeated measurements from the field may be
more reliable than a single measurement. Thus although inter-
institutional differences may have affected the absolute values
obtained in this study, it is likely that trends (repeated values
from the same sites) were less affected.
Summary
Left ventricular hypertrophy and significant mitral valve
obstruction are reported in 54 individuals with MPS VI
ranging from 6 to 29 years of age undergoing treatment
trials with galsulfase. Long-term enzyme replacement with
galsulfase was associated with stable left ventricular func-
tion in all subjects and regression of intraventricular septal
hypertrophy when enzyme therapy began before the age of
12 years. Despite long-term enzyme therapy, cardiac valve
stenosis remained unchanged in all subjects. Aortic regurgi-
tation increased statistically, but not physiologically, only in
those who began enzyme at 12 or more years of age. The
evidence presented suggests that the underlying pathologi-
cal changes due to GAG accumulation, especially in the
valves, may be poorly reversible and that early initiation
of galsulfase therapy may be beneficial.
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